Several novel human host defence peptides were identified, some of which have shown interesting LPS binding ability. These LPS binding molecules showed activity on Gram positive and negative bacteria including several CF clinical strains; moreover, no toxicity was found in different human cell lines. Experiments carried out on human and murine LPS treated macrophages highlighted significant propensity to mitigate cytokine and chemokine expression. Next step will be to verify these LPS neutralizing properties in CF murine models. This evidence suggests new perspectives on topic therapeutic use of these bioactive peptides.